- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05201872
Bacteriological Differences Between Transanal and Laparoscopic Total Mesorectal Excision for Rectal Cancer.
January 21, 2022 updated by: Yanhong Deng
The primary purpose of this study is to compare the differences of bacteriological in rectal cancer patients undergoing laparoscopic or transanal endoscopy radical resection.
The secondary purpose is to compare the effects of two different surgical methods on postoperative complications.
Study Overview
Status
Recruiting
Conditions
Detailed Description
Transanal total mesorectal excision (taTME) is a new surgical procedure for total mesorectal excision (TME) by dissociating the mesorectum from the bottom through transanal endoscopic.
The characteristics of TaTME are mainly summarized as transanal reverse operation, no auxiliary abdominal incision, complete mesorectal excision and specimen removal through the anus.
So taTME is a natural orifice specimen extraction procedure (NOSES).
Compared with traditional laparoscopy, taTME has obvious oncological and technical advantages.
However, similar to NOSES, the specific surgical approach to taTME may induces bacteriological safety concerns.
Whether TaTME is safe and feasible still needs strong evidence-based medical evidence.
However, there have been prospective studies related to bacteriology in NOSES surgery, but there is a lack of prospective clinical studies on the issue of bacteriological diffusion during taTME surgery.
Bacterial contamination of the peritoneal cavity is common in laparoscopic surgery for colorectal cancer.
Although the standard NOSES procedure avoids bacteriological problems through the use of antibiotics, surgical peritoneal irrigation, and the use of sterile specimen bags, its safety remains inconclusive.
Therefore, compared with conventional laparoscopic colorectal cancer surgery, taTME not only takes specimens from the natural orifice, but also requires further prospective studies on whether the incision of the intestinal wall from the mucosa during the operation will violate the aseptic principle, the aseptic safety of taTME still needs further prospective studies to confirm.
Therefore, the investigators conducted a randomized controlled study to collect the abdominal and pelvic irrigation fluids in the transanal and laparoscopic TME surgery for bacteriological examination, to clarify the influence of the two different surgical methods on the intraoperative bacterial diffusion.
The purpose of this study was to clarify the influence of two different surgical methods on the intraoperative bacterial spread, and to provide more evidence-based medical evidence for the safety of taTME surgery.
Study Type
Observational
Enrollment (Anticipated)
216
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Liang Huang
- Phone Number: 15989101216
- Email: huangl75@mail.sysu.edu.cn
Study Contact Backup
- Name: Mian Chen
- Phone Number: 13711370070
- Email: chenmian1997@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510655
- Recruiting
- Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University
-
Contact:
- Liang Huang, MD, PhD
- Phone Number: 15989101216
- Email: huangl75@mail.sysu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
216 rectal cancer patients will be enrolled.
Patients must be older than 18 years.
Description
Inclusion Criteria:
- Primary rectal carcinoma
- Single lesion
- No metastasis
Exclusion Criteria:
- History of malignant tumors
- Acute bowel obstruction, bleeding or perforation
- Tumor over 6cm in diameter or in severe adhesion with surrounded tissues
- Severe other contradictions of surgery
- Pregnant women will be excluded
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
laparoscopic surgery
Different surgical methods for rectal cancer resection
|
|
Transanal endoscopic surgery
Different surgical methods for rectal cancer resection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The positive rate of bacterial contamination of peritoneal washings
Time Frame: 1 years
|
Bacterial contamination positive rate determined by bacterial culture of intra-operative peritoneal washings
|
1 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative complications
Time Frame: a month
|
Determine whether patients have postoperative complications after surgery
|
a month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 15, 2022
Primary Completion (Anticipated)
February 1, 2023
Study Completion (Anticipated)
April 1, 2023
Study Registration Dates
First Submitted
January 20, 2022
First Submitted That Met QC Criteria
January 20, 2022
First Posted (Actual)
January 21, 2022
Study Record Updates
Last Update Posted (Actual)
February 7, 2022
Last Update Submitted That Met QC Criteria
January 21, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GIHSYSU-21
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectum Cancer
-
Washington University School of MedicineCompletedRectal Cancer | Cancer of Rectum | Cancer of the Rectum | Neoplasm, Rectum | Rectum Cancer | Rectum Neoplasms | Adenocarcinoma of the RectumUnited States
-
Wuhan Union Hospital, ChinaRecruitingRectal Cancer | Cancer of Rectum | Cancer of the Rectum | Rectum Cancer | Rectum Neoplasms | Neoplasms, Rectal | Rectal TumorsChina
-
Necmettin Erbakan UniversityTurkish Society of Medical OncologyRecruiting
-
Vejle HospitalAarhus University HospitalTerminated
-
San Carlo di Nancy HospitalRecruitingColorectal Cancer | Anastomotic Leak | Colon Cancer | Colon Neoplasm | Rectum Cancer | Rectum Neoplasm | Anastomotic Leak Rectum | Anastomotic Leak Large IntestineItaly
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityCompletedLocal Recurrence of Malignant Tumor of Rectum | Local Re-Recurrence of Malignant Tumor of Rectum
-
AC Camargo Cancer CenterUnknownColon Cancer Stage IIb | Rectum Cancer, Adenocarcinoma | Colon Cancer Stage IIIa | Colon Cancer Stage IIIc | Colon Cancer Stage IIIbBrazil
-
Mater Misericordiae University HospitalPenn State University; Københavns Universitet; Krankenhaus der Barmherzigen Bruder... and other collaboratorsRecruitingRectal Cancer | Rectum Neoplasm | Rectum PolypIreland
-
First Ascent Biomedical Inc.Mayo Clinic; Florida International UniversityNot yet recruitingMetastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Metastatic Colon Cancer | Metastatic Rectal Carcinoma | Metastatic Rectum Cancer
-
Peking University Third HospitalCompleted